(Q44180072)

30 November 2017

title

Budesonide induction and maintenance therapy for Crohn's disease during pregnancy (English)

1 reference

30 November 2017

1 reference

8

Mary F Otterson

1 reference

30 November 2017

Dawn B Beaulieu

1

1 reference

30 November 2017

Ashwin N Ananthakrishnan

2

1 reference

30 November 2017

Mazen Issa

3

1 reference

30 November 2017

Lydia Rosenbaum

4

1 reference

30 November 2017

Sue Skaros

5

1 reference

30 November 2017

Julianne R Newcomer

6

1 reference

30 November 2017

Randall S Kuhlmann

7

1 reference

30 November 2017

Jeanne Emmons

9

1 reference

30 November 2017

Josh Knox

10

1 reference

30 November 2017

David G Binion

11

1 reference

30 November 2017

publication date

1 January 2009

1 reference

Inflammatory Bowel Diseases

30 November 2017

published in

1 reference

30 November 2017

volume

15

1 reference

30 November 2017

issue

1

1 reference

30 November 2017

page(s)

25-28

1 reference

European evidence based consensus on the diagnosis and management of Crohn's disease: special situations

30 November 2017

cites work

1 reference

Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California

21 January 2018

1 reference

Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study.

21 January 2018

1 reference

Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease

21 January 2018

1 reference

The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications

21 January 2018

1 reference

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

21 January 2018

1 reference

Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials

21 January 2018

1 reference

Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States

21 January 2018

1 reference

Oral budesonide as maintenance therapy in Crohn's disease--results of a 12-month study. Global Budesonide Study Group.

21 January 2018

1 reference

Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial

21 January 2018

1 reference

Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study

21 January 2018

1 reference

A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

21 January 2018

1 reference

Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonide

21 January 2018

1 reference

Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial

21 January 2018

1 reference

Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries

21 January 2018

1 reference

Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IBD.20640

1 reference

30 November 2017

1 reference